Raboisson, Pierre Jean-Marie Bernard,Last, Stefaan,Vandyck, Koen,Rombouts, Geert,Verschueren, Wim Gaston
申请号：
NZ74346313
公开号：
NZ743463A
申请日:
2013.08.28
申请国别(地区):
NZ
年份:
2019
代理人:
摘要：
The Hepatitis B virus (HBV) has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma. An effective and well-tolerated vaccine exists, but direct treatment options are currently limited to interferon and the following antivirals； tenofovir, lamivudine, adefovir, entecavir and telbivudine. Amongst the problems which HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability and difficulty of synthesis. Thus, there is a need for additional HBV inhibitors that may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window. The present invention relates to inhibitors of HBV replication, pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.
